Author, date, study type, level of evidence, Heyland score

Patient group

Complications reported

Nutritional outcomes

Dann et al. 2015

Retrospective Cohort Study

CEBM Level 4

Heyland Score (/11): 5

Total = 492

J-tube group = 79 (16.1%)

No J-tube

= 413 (83.9%)

Any Complication:

35.4% JT vs. 34.1% No JT

Major Complication^{^}:

11.4% JT vs. 12.8% No JT

Infectious Complication*:

27.8% JT vs. 16.9% No JT

Surgical Site Infection:

12.7% JT vs. 4.6% No JT*

Deep Intra-Abdominal Infection:

7.6% JT vs. 3.1% No JT

Reoperation:

3.8% JT vs. 4.6% No JT

30-Day Readmission:

10.1% JT vs. 11.6% No JT

Length of Stay (days):

12.4 (±8.8) JT vs. 9.6 (±8.7) No JT*

Adjuvant Chemotherapy:

52.0% JT vs. 51.0% No JT

Adjuvant Radiation Therapy:

38.7% JT vs. 32.5% No JT

Any Adjuvant Therapy:

52.0% JT vs. 51.8% No JT

Patel et al. 2013

Retrospective Cohort Study

CEBM Level 4

Heyland Score (/11): 5

Total = 86

J-tube: 34 (39.5%)

No J-tube: 52 (60.5%)

Any Complication:

65% JT vs. 40% No JT*

Infectious Complication:

38% JT vs. 17% No JT*

Major Complication^{^}:

15% JT vs. 8% No JT

Reoperation:

3% JT vs. 2% No JT

Bleeding Requiring Packed RBC Transfusion:

3% JT vs. 0% No JT

Anastomotic Leak:

0% JT vs. 2% No JT

30-Day Readmission:

6% JT vs. 15% No JT

Length of Stay (days):

13 (7 - 33)^a JT vs. 11 (2 - 52)^a No JT

Albumin Pre-Operative:

3.5 (2.2 - 4.4)^a JT vs. 3.5 (2.2 - 4.6)^a No JT

Albumin 30-Day:

3.3 (1.8 - 4.3)^a JT vs. 3.2 (1.2 - 4.4)^a No JT

Albumin 60-Day:

3.7 (3.0 - 4.4)^a JT vs. 3.5 (2.1 - 4.4)^a No JT

Albumin 90-Day:

3.4 (1.4 - 4.3)^a JT vs. 3.4 (1.5 - 4.2)^a No JT

Received Adjuvant Therapy Post-Op:

56% JT vs. 52% No JT